Historique
Livre
Hepatitis C and injecting drug use: impact, costs and policy options
(Hépatite C et injection de drogues : prévalence, coût social et choix politiques)
Auteur(s) :
JAGER J. ;
LIMBURG W. ;
KRETZSCHMAR, M. ;
POSTMA M. ;
WIESSING, L. (Éditeur scientifique)
Année
2004
Page(s) :
389 p.
Langue(s) :
Anglais
Éditeur(s) :
Lisbon : OEDT / EMCDDA
;
Luxembourg : Office for Official Publications of the European Communities
Collection :
Monographs, N°7
ISBN :
978-92-9168-168-7
Domaine :
Drogues illicites / Illicit drugs
Discipline :
EPI (Epidémiologie / Epidemiology)
Thésaurus géographique
UNION EUROPEENNE
Thésaurus mots-clés
HEPATITE
;
INJECTION
;
COUT SOCIAL
;
QUALITE DE VIE
;
PREVENTION
;
PREVALENCE
;
TRAITEMENT
;
EVALUATION
;
ECHANGE DE SERINGUES
;
METHADONE
;
REDUCTION DES RISQUES ET DES DOMMAGES
Organismes
OEDT
Résumé :
ENGLISH :
Hepatitis C infections occurring in recent years in the European Union may cost countries billions of euros in future healthcare, according to research published in this monograph.
A conglomeration of state-of-the-art research on hepatitis C, drug use and public health methods, this publication presents analyses on the impact and costs of the disease among injecting drug users, as a basis for sound policy-making. Other issues addressed include: quality of life; treatment, surveillance and prevention; and the cost-effectiveness of measures such as needle-exchange programmes and substitution therapy.
Hepatitis C affects an estimated 170 million people worldwide and at least a million, but possibly several million, people in Western Europe who are at risk of developing liver cirrhosis or liver cancer. It is a highly infectious and potentially fatal blood-borne disease that attacks the liver and for which there is as yet no vaccine. [Editor's abstract]
Hepatitis C infections occurring in recent years in the European Union may cost countries billions of euros in future healthcare, according to research published in this monograph.
A conglomeration of state-of-the-art research on hepatitis C, drug use and public health methods, this publication presents analyses on the impact and costs of the disease among injecting drug users, as a basis for sound policy-making. Other issues addressed include: quality of life; treatment, surveillance and prevention; and the cost-effectiveness of measures such as needle-exchange programmes and substitution therapy.
Hepatitis C affects an estimated 170 million people worldwide and at least a million, but possibly several million, people in Western Europe who are at risk of developing liver cirrhosis or liver cancer. It is a highly infectious and potentially fatal blood-borne disease that attacks the liver and for which there is as yet no vaccine. [Editor's abstract]
Affiliation :
Portugal